Partner
Jaideep Dudani
Principal (Portfolio), PhD, BS, Monograph Capital
- Firm
- Monograph Capital
- Title
- Principal (Portfolio), PhD, BS
- Role
- Principal
- Known as
- Investor
Record updated 19 September 2026
About
Jaideep Dudani is a Principal at Monograph Capital and the founding CEO of Ouro Medicines, a Monograph Capital portfolio company. He currently serves on the board of Ouro Medicines and as an observer on the board of Sudo Biosciences. He was part of the founding team of Human Immunology Biosciences (HI-Bio), another Monograph Capital portfolio company, where he led portfolio development and strategy prior to the acquisition by Biogen. Prior to Monograph Capital, he was at Relay Therapeutics, a precision medicine company focused on oncology and rare genetic diseases, where he played a cross-functional role in R&D and strategy and business development and was part of the team that took the company public. Before Relay, Jaideep was the first associate at Vida Ventures, and was involved in several of Vida’s investments, including Allogene Therapeutics (NASDAQ: ALLO), Asklepios BioPharmaceutical (which was acquired by Bayer AG in 2020), Oyster Point Pharma (acquired by Viatris), Kyverna (NAS
Is this you? Remove my profile